Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra

Arthritis and Rheumatism

Volumn 39, Issue 5, 1996, Pages 797-809

  Joosten, Leo A B ^a   Helsen, Monique M A ^a   Van De Loo, Fons A J ^a   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; ARTICULAR CARTILAGE; AUTORADIOGRAPHY; COLLAGEN METABOLISM; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATORY CELL; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES; ARTHRITIS, RHEUMATOID; COLLAGEN; CYTOKINES; IMMUNOTHERAPY; INFUSION PUMPS; INTERLEUKIN-1; JOINTS; MALE; MICE; MICE, INBRED DBA; RECEPTORS, INTERLEUKIN-1; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029875804     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390513     Document Type: Article

References (59)

1. Firestein GS, Alvaro-Garcia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144:3347-3353, 1990
2. Chen E, Keystone EC, Fish EN: Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 36:901-910, 1993
3. Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38:151-160, 1995
4. Dayer JM, Fenner H: The role of cytokines and their inhibitors in arthritis. Ballieres Clin Rheumatol 6:485-516, 1992
5. Chikanza IC, Roux-Lombard P, Dayer J-M, Panayi GS: Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 38:642-648, 1995
6. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247, 1989
7. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031, 1991
8. Piquet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-514, 1992
9. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joints disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784-9788, 1992
10. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 36:1681-1690, 1993
11. Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen J, Leeb B, Breedveld EC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
12. Rankin ECC, Choy EHS, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334-342, 1995
13. Trentham DE, Townes AS, Rang AH: Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146: 857-868, 1977
14. Courtenay JS, Dallman MJ, Dayan AB, Martin A, Mosedale B: Immunization against heterologous type II collagen-induced arthritis in mice. Nature 2843:666-668, 1980
15. Wooley PH, Luthra HS, Stuart JM, David CS: Type II collagen-induced arthritis in mice: I. major histocompatibility complex (I-region) linkage and antibody correlates. J Exp Med 154:688-700, 1981
16. Stuart JM, Townes AS, Kang AH: Nature and specificity of immune responses to collagen in type II collagen-induced arthritis in mice. J Clin Invest 69:673-683, 1982
17. Killar LM, Dunn CJ: Interleukin-1 potentiates the development of collagen-induced arthritis in mice. Clin Sci (Colch) 76:535-538, 1989
18. Horn JT, Bendele AM, Cartson DG: In vivo administration with IL-1 accelerates the development of collagen-induced arthritis. J Immunol 141:834-841, 1988
19. Cooper WO, Fava RA, Gates CA, Cremer MA, Townes AS: Acceleration of onset of collagen-induced arthritis by intraarticular injection of tumor necrosis factor and transforming growth factor-beta. Clin Exp Immunol 89:244-250, 1992
20. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA: Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375-7379, 1992
21. Santambrogio L, Hochwald GM, Leu GH, Thorbecke GJ: Antagonistic effects of endogenous and exogenous TGF-β and TNFα on auto-immune diseases in mice. Immunopharmacol Immunotoxicol 15:461-478, 1993
22. Wooley PH, Dutcher J, Widmer MB, Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607, 1993
23. Geiger T, Towbin H, Cosenti-Vargas A, Zingel O, Arnold J, Rordorf C, Glatt M, Vosbeck K: Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol 11:515-522, 1993
24. Van den Berg WB, Joosten LAB, Helsen MMA, Van de Loo AAJ: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 95:237-243, 1994
25. Van de Loo AAJ, Arntz OJ, Otterness IG, van den Berg WB: Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin-1 antibodies in experimental arthritis. J Rheumatol 19:348-356, 1992
26. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB: Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 38:164-172, 1995
27. Shire D: An invitation to an open exchange of reagents and information useful for the measurement of cytokine mRNA levels by PCR. Eur Cytokine Netw 4:161-172, 1993
28. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous TNF or cachectin for recovery from experimental peritonitis. J Immunol 145:3762-3766, 1990
29. Miller EJ, Rhodes RK: Preparation and characterization of the different types of collagen. Methods Enzymol 82:33-65, 1982
30. Caccese RG, Zimmerman JL, Carlson RP: Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice. Mediators Inflamm 1:273-279, 1992
31. Joosten LAB, Helsen MMA, van den Berg WB: Accelerated onset of collagen-induced arthritis by remote inflammation. Clin Exp Immunol 97:204-211, 1994
32. Van den Broek MF, van den Berg WB, van de Putte LBA, Severijnen AJ: Streptococcal cell wall induced arthritis and flare-up reactions in mice induced by homologous and heterologous cell walls. Am J Pathol 133:139-149, 1988
33. 99mTc-pertechnetate uptake. Agents Actions 11:640-642, 1981
34. Van den Berg WB, van de Putte LBA, Zwarts ZW, Joosten LAB: Electrical charge of the antigen determines intraarticular antigen handling and chronicity of arthritis in mice. J Clin Invest 74:1850-1859, 1984
35. Van Osch GJVM, van der Kraan PM, van den Berg PM: Site-specific cartilage changes in murine degenerative knee joint disease induced by iodoacetate and collagenase. J Orthop Res 12:168-175, 1994
36. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
37. Nasrin N, Colanil E, Denaro M, Kong XF, Kang I, Alexander M: An insulin response element in the glyceraldehyde-3-phosphatase dehydrogenase gene binds a nuclear protein induced by insulin in cultured cells. Proc Natl Acad Sci USA 87:5273-5277, 1990
38. Montgomery RA, Dallman PS: Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction. J Immunol 147:554-560, 1991
39. Chensue SW, Bienkowski M, Eessalu TE, Warmington KS, Hershey SD, Lukacs NW, Kunkel SL: Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosoma egg granuloma formation and the regional lymphoid response. J Immunol 151:3654-3662, 1993
40. Murray LJ, Lee R, Martens C: In vivo cytokine expression in T-cell subset of the autoimmune MRL/MP-1pr/lpr mouse. Eur J Immunol 20:163-170, 1990
41. Wang AM, Doyle MV, Mark DF: Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A 86:9717-9721, 1989
42. Williams RO, Mason LJ, Feldmann M, Maini RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A 91:2762-2766, 1994
43. Plater-Zyberk C, Taylor PC, Blaylock MG, Maini RN: Anti-CD5 therapy decreases severity of established collagen type II-induced arthritis in DBA-1 mice. Clin Exp Immunol 98:442-447, 1994
44. Maeda T, Saikawa I, Hotokebuchi T, Sugioka Y, Eto M, Murakami Y, Nomoto K: Exacerbation of established collagen-induced arthritis in mice treated with an anti-T cell receptor antibody. Arthritis Rheum 37:406-413, 1994
45. Van den Berg WB, Joosten LAB, Helsen MA, van Lent PLEM, van de Loo FAJ: Cytokine profile dependent on the type of arthritis: dominant role of IL-1 in cartilage destruction (abstract). Arthritis Rheum 37 (suppl 9):S193, 1994
46. Schwab JH, Brown RR, Anderle SK, Schlievert PM: Superantigen can reactivate bacterial cell wall induced arthritis. J Immunol 150:4151-4159, 1993
47. Arend WP, Welgus HG, Thompson HG, Eisenberg SP: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 85:1694-1697, 1990
48. Arend WP: Interleukin-1 receptor antagonist. Adv Immunol 54:167-227, 1993
49. Wooley PH, Whalen JD, Chapman DL, Berger AE, Richard KA, Aspar DG, Staite ND: The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice. Arthritis Rheum 36:1305-1314, 1993
50. Lewthwaite J, Blake SM, Hardingham TM, Warden PJ, Henderson B: The effect of recombinant human IL-1 receptor antagonist on the induction of antigen-induced arthritis in the rabbit. J Rheumatol 21:467-472, 1994
51. Van de Loo AAJ, Arntz OJ, Bakker AC, van Lent PLEM, Jacobs MJM, van den Berg WB: Role of interleukin-1 in antigen-induced exacerbations of murine arthritis. Am J Pathol 146:239-249, 1995
52. Van Lent PLEM, van den Bersselaar LAM, van den Hoek AEM, van de Loo AAJ, van den Berg WB: Cationic immune complex arthritis in mice: a new model. Synergistic effect of complement and interleukin-1. Am J Pathol 140:1451-1461, 1992
53. Probert L, Plows D, Kontogeorgos G, Kollias G: The type I interleukin receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 25:1794-1798, 1995
54. Saklatvala J: Tumor necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547-549, 1986
55. Henderson B, Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumor necrosis factor α in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 75:306-310, 1989
56. Holmdahl R, Malmstrom V, Vuorio E: Autoimmune recognition of cartilage collagens. Ann Med 25:251-264, 1993
57. Villiger PM, Terkeltaub R, Lotz M: Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 149:722-727, 1992
58. Van de Langerijt AGM, Kingston AE, van Lent PLEM, Billingham MEJ, van den Berg WB: Cross-reactivity to proteoglycans in bacterial arthritis: lack of evidence for in vivo role in induction of disease. Clin Immunol Immunopathol 71:273-280, 1994
59. Li P, Allen H: Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 80:401-411, 1995